Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model

  • Hoth Therapeutics Inc HOTH has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model
  • The model showed that HT-003 reduces toll-like receptor 2 (TLR2) expression, one of the most critical pathways for acne pathophysiology. 
  • The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.
  • HT-003 is a group of retinoic acid metabolism blocking agents, novel agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body.
  • In addition to the dermatologic application, Hoth Therapeutics is exploring the potential application of HT-003 assets in inflammatory bowel disorders.
  • Price Action: HOTH shares are down 2.01% at $1.46 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!